BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive tumor; treatment remains a challenge because of the lack of effective therapeutic strategies. Basic research in this field is dependent on the availability of model systems. New pancreatic cancer cell lines are therefore important for the study of its biology. In the present study, we report the establishment and characterization of five new pancreatic cancer cell lines (PaCaDD-43, -60, -119, -135, -137). MATERIAL AND METHODS: All cell lines were derived from pancreatic ductal adenocarcinomas by the Dresden outgrowth protocol. The five cell lines originated from primary pancreatic tumors, lymph node metastases, or malignant pleural effusions. We characterized the cell lines by examining their morphology and their cytostructural and functional profiles. RESULTS: All cell lines grew as adherent monolayers and were cultured in optimized Dresden-medium. The doubling time ranged from 22 to 47 h. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were detected in four of the five cell lines. KRAS mutations were identical between each primary tumor and the cell line derived from it. Immunohistochemical staining showed cytoplasmic expression of CK8/18, mostly membrane and partially cytoplasmic expression of E-cadherin and strong expression of ezrin in all cell lines. Three cell lines showed nuclear p53 accumulation and heterogeneous expression of vimentin. SMAD4 was heterogeneously expressed in four of the cell lines. CONCLUSIONS: We were able to establish five new primary pancreatic carcinoma cell lines. As applicable tools for basic research, these cell lines might contribute to a better understanding and treatment of this aggressive tumor.
BACKGROUND:Pancreatic ductal adenocarcinoma is an aggressive tumor; treatment remains a challenge because of the lack of effective therapeutic strategies. Basic research in this field is dependent on the availability of model systems. New pancreatic cancer cell lines are therefore important for the study of its biology. In the present study, we report the establishment and characterization of five new pancreatic cancer cell lines (PaCaDD-43, -60, -119, -135, -137). MATERIAL AND METHODS: All cell lines were derived from pancreatic ductal adenocarcinomas by the Dresden outgrowth protocol. The five cell lines originated from primary pancreatic tumors, lymph node metastases, or malignant pleural effusions. We characterized the cell lines by examining their morphology and their cytostructural and functional profiles. RESULTS: All cell lines grew as adherent monolayers and were cultured in optimized Dresden-medium. The doubling time ranged from 22 to 47 h. v-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog (KRAS) mutations were detected in four of the five cell lines. KRAS mutations were identical between each primary tumor and the cell line derived from it. Immunohistochemical staining showed cytoplasmic expression of CK8/18, mostly membrane and partially cytoplasmic expression of E-cadherin and strong expression of ezrin in all cell lines. Three cell lines showed nuclear p53 accumulation and heterogeneous expression of vimentin. SMAD4 was heterogeneously expressed in four of the cell lines. CONCLUSIONS: We were able to establish five new primary pancreatic carcinoma cell lines. As applicable tools for basic research, these cell lines might contribute to a better understanding and treatment of this aggressive tumor.
Authors: Kien Pham; Daniel Delitto; Andrea E Knowlton; Emily R Hartlage; Ricky Madhavan; David H Gonzalo; Ryan M Thomas; Kevin E Behrns; Thomas J George; Steven J Hughes; Shannon M Wallet; Chen Liu; Jose G Trevino Journal: Am J Pathol Date: 2016-04-18 Impact factor: 4.307
Authors: Amira Elgogary; Qingguo Xu; Brad Poore; Jesse Alt; Sarah C Zimmermann; Liang Zhao; Jie Fu; Baiwei Chen; Shiyu Xia; Yanfei Liu; Marc Neisser; Christopher Nguyen; Ramon Lee; Joshua K Park; Juvenal Reyes; Thomas Hartung; Camilo Rojas; Rana Rais; Takashi Tsukamoto; Gregg L Semenza; Justin Hanes; Barbara S Slusher; Anne Le Journal: Proc Natl Acad Sci U S A Date: 2016-08-24 Impact factor: 11.205
Authors: Lisa Hunihan; Dejian Zhao; Heather Lazowski; Man Li; Yuping Qian; Laura Abriola; Yulia V Surovtseva; Viswanathan Muthusamy; Lynn T Tanoue; Bonnie E Gould Rothberg; Kurt A Schalper; Roy S Herbst; Frederick H Wilson Journal: Clin Cancer Res Date: 2022-07-15 Impact factor: 13.801
Authors: Weijing Cai; Ranjala Ratnayake; Michael H Gerber; Qi-Yin Chen; Yichao Yu; Hartmut Derendorf; Jose G Trevino; Hendrik Luesch Journal: Invest New Drugs Date: 2018-08-03 Impact factor: 3.850
Authors: Stephan B Dreyer; Rosie Upstill-Goddard; Viola Paulus-Hock; Clara Paris; Eirini-Maria Lampraki; Eloise Dray; Bryan Serrels; Giuseppina Caligiuri; Selma Rebus; Dennis Plenker; Zachary Galluzzo; Holly Brunton; Richard Cunningham; Mathias Tesson; Craig Nourse; Ulla-Maja Bailey; Marc Jones; Kim Moran-Jones; Derek W Wright; Fraser Duthie; Karin Oien; Lisa Evers; Colin J McKay; Grant A McGregor; Aditi Gulati; Rachel Brough; Ilirjana Bajrami; Stephan Pettitt; Michele L Dziubinski; Juliana Candido; Frances Balkwill; Simon T Barry; Robert Grützmann; Lola Rahib; Amber Johns; Marina Pajic; Fieke E M Froeling; Phillip Beer; Elizabeth A Musgrove; Gloria M Petersen; Alan Ashworth; Margaret C Frame; Howard C Crawford; Diane M Simeone; Chris Lord; Debabrata Mukhopadhyay; Christian Pilarsky; David A Tuveson; Susanna L Cooke; Nigel B Jamieson; Jennifer P Morton; Owen J Sansom; Peter J Bailey; Andrew V Biankin; David K Chang Journal: Gastroenterology Date: 2020-10-09 Impact factor: 22.682